Prostate-specific antigen is a predictor of the efficacy of salvage radiation therapy in patients with recurrent prostate cancer after radical prostatectomy

The study objective is to determine advisability of radiation therapy in patients with recurrent prostate cancer after radical prostatectomy.

Materials and methods. In our research 92 patients were treated by salvage radiation therapy after radical prostatectomy. The median of follow up is 48 months.

Results. The rates of 1, 2 and 3 years disease-free survival were 96, 91 and 86 %. We received that prostate specific antigen doubling time <6 months and prostate specific antigen >0.5 ng/ml before salvage radiation therapy statistical significance associated with biochemical failure. The results of our study indicate two main negative factors in the prognosis of the efficacy of radiotherapy and combined hormone therapy in patients with biochemical or clinical locoregional recurrence – the period of prostate specific antigen doubling time less than 6 months (p = 0.035) after radical prostatectomy and a higher prostate specific antigen level, especially more than 0.5 ng/ml before salvage radiotherapy (p = 0.037).

Conclusion. Taking into account the absence of differences in the results of treatment between groups of patients with clinical and biochemical recurrences, it is not advisable to postpone the implementation of salvage radiotherapy and recommend patients to repeat the study. Repeated studies of these patients, as a rule, are conducted after many months at a higher level of the prostate specific antigen, which is associated with a higher tumor activity and a worse prognosis of the disease.

1. Cookson M.S., Aus G., Burnett A.L. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer. the American Urological Association Prostate Guidelines for Localized Prostate Cancer. Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urology 2007;177(2):540–5. DOI: 10.1016/j.juro.2006.10.097. PMID: 17222629.

2. Boccon-Gibod L., Djavan W.B., Hammerer P. et al. Management of prostatespecific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382–90. PMID: 15161124.

3. Stephenson A.J., Scardino P.T., Kattan M.W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035–41. DOI: 10.1200/JCO.2006.08.9607. PMID: 17513807.

4. Siegmann A., Bottke D., Faehndrich J. et al. Salvage radiotherapy after prostatectomy – what is the best time to treat? Radiother Oncol 2012;103(2):239–43. DOI: 10.1016/j.radonc.2011.10.024. PMID: 22119375.

5. . Shelan M., Abo-Madyan Y., Welzel G. et al. Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. Radiat Oncol 2013;8:276. DOI: 10.1186/1748-717X-8-276. PMID: 24279376.

6. Kwon O., Kim K.B., Lee Y.I. et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One 2014;9(7):e103574. DOI: 10.1371/journal.pone.0103574. PMID: 25072938.

7. Miyake M., Tanaka N., Asakawa I. et al. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. Radiat Oncol 2014;9:208. DOI: 10.1186/1748-717X-9208. PMID: 25331298.

8. Botticella A., Guarneri A., Levra N.G. et al. Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. Clin Oncol 2014;140(7):1111–6. DOI: 10.1007/s00432-014-1673-8. PMID: 24744191.

9. Safdieh J.J., Schwartz D., Weiner J. et al. Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy. J Radiat Oncol 2014;32(3):179–86. DOI: 10.3857/roj.2014.32.3.179. PMID: 25324990.

10. Lohm G., Lütcke J., Jamil B. et al. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: long-term follow-up of a single-center survey. Strahlenther Onkol 2014;190(8):727–31. DOI: 10.1007/s00066-014-0612-6. PMID: 24577132.

11. Briganti A., Karnes R.J., Joniau S. et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014;66(3):479–86. DOI: 10.1016/j.eururo.2013.11.045. PMID: 24345725.

12. Ploussard G., Staerman F., Pierrevelcin J. et al. Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatec tomy: results from a national multicen tre study. World J Urol 2014;32(5):1331–8. DOI: 10.1007/s00345-013-1214-0. PMID: 24270970.